Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07497360
Recruiting Observational

Tele-assessment and Face-to-face Assessment of the 30-second Sit-stand Test in Peripheral Artery Disease

NCT07497360 · tracked via the Priya Life Science Turkey tracker
Sponsor
Izmir Democracy University
Phase
Observational
Started
2026-02-10
Last updated
2026-03-27

Condition(s) studied

Peripheral Arterial Disease

Study summary

Peripheral artery disease (PAD) is a chronic and progressive condition caused by narrowing or blockage of arteries in the lower limbs due to atherosclerosis. It primarily affects adults over 50, with prevalence increasing with age, and its clinical presentation ranges from asymptomatic cases to severe ischemia that may require amputation. Intermittent claudication, characterized by exercise-induced leg pain that resolves with rest, is the most common early symptom. Impaired blood flow, poor vascularization, and muscle loss contribute to reduced lower limb strength and functional capacity, which are associated with higher morbidity and mortality.

Walking exercises is a cornerstone of PAD management, particularly for patients with no or mild symptoms, making the assessment of lower limb strength and mobility essential for designing rehabilitation programs. The 30-second sit-to-stand test is a validated and practical measure of functional capacity and walking ability. Tele-assessment using video technology has been shown to be feasible and reliable in other patient populations. Although tele-rehabilitation has been widely studied and shown to improve functional outcomes, research on tele-assessment methods to accurately evaluate patient performance and the effectiveness of rehabilitation programs is still limited, particularly in PAD patients.

This study aims to examine the reliability of the 30-second sit-to-stand test when performed via tele-assessment compared with face-to-face evaluation in patients with PAD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 18 and 65 years * Diagnosed with peripheral artery disease, Fontaine stage I-II, confirmed by peripheral angiography or Doppler ultrasonography * Willingness to participate in the study * Access to a smartphone and the internet Exclusion Criteria: * Presence of orthopedic, neurological, or psychological conditions that limit physical activity * Neurological or musculoskeletal disorders affecting standing or walking * History of ischemic amputation * Acute inflammatory condition * Use of walking aids * Visual or hearing impairment * Vestibular system disorder * Cognitive impairment affecting cooperation * Severe cardiopulmonary diseases limiting walking ability * Major surgery or myocardial infarction within the last three months * Unstable coronary artery disease

Primary outcome measure(s)

  • Lower Extremity Function — From February 2026 to June 2026
    Lower extremity strength and functional mobility will be evaluated using the 30-second sit-to-stand test. Participants will sit on a 44 cm high chair with a backrest and no armrests, arms crossed over the shoulders, and will be instructed to stand and sit as many times as possible within 30 seconds. The number of complete repetitions will be recorded.

Trial sites (1)

FacilityCityRegionStatus
Dokuz Eylul University Faculty of Medicine Izmir Balçova Recruiting

More Izmir Democracy University trials in Turkey

Respiratory and Physical Outcomes in Different Types of Office Workers Active, not recruiting
Artificial Intelligence-Assisted Posture Applicatıon Recruiting
Injury Risk Factors in Volleyball Players Recruiting
Validity of the Turkish Translation of the Modified JOA Recruiting
The Validity and Reliability of the OMERACT in the Turkish Population Recruiting

Other trials for the same condition

Evaluation of the Effectiveness of Hybrid Cardiac Rehabilitation in Peripheral Artery Disease Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07497360 on ClinicalTrials.gov ↗ ← All trials in Turkey